The AXL receptor tyrosine kinase is associated with adverse prognosis and distant metastasis in esophageal squamous cell carcinoma

Oncotarget

Volumn 7, Issue 24, 2016, Pages 36956-36970

  Hsieh, Min Shu ^a,b   Yang, Pei Wen ^a   Wong, Li Fan ^a   Lee, Jang Ming ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

AXL; Esophageal cancer; Esophageal squamous cell carcinoma; HER2; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AXL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FORETINIB; LAPATINIB; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG; ANILIDE; AXL RECEPTOR TYROSINE KINASE; ERBB2 PROTEIN, HUMAN; ONCOPROTEIN; QUINOLINE DERIVATIVE; TUMOR MARKER;

ADULT; ADVERSE OUTCOME; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOMA CELL; CHEMOSENSITIVITY; CONTROLLED STUDY; DISTANT METASTASIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGEAL TISSUE; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY TUMOR; PROTEIN EXPRESSION; AGED; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; ESOPHAGUS TUMOR; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR INVASION;

ADULT; AGED; ANILIDES; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; QUINOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, ERBB-2;

EID: 84978043581     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.9231     Document Type: Article

References (58)

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010; 19:1893-1907.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24:2137-2150.
3. Miyashita M, Tajiri T, Sasajima K, Makino H, Maruyama H, Nomura T, Futami R, Hagiwara N, Tsuchiya Y, Yamashita K. Response to preoperative chemotherapy affects prognosis in esophageal cancer. Dis Esophagus. 2003; 16:99-101.
4. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009; 27:5062-5067.
5. Enzinger PC, Mayer RJ. Esophageal cancer. N Engl J Med. 2003; 349:2241-2252.
6. Almhanna K, Meredith KL, Hoffe SE, Shridhar R, Coppola D. Targeting the human epidermal growth factor receptor 2 in esophageal cancer. Cancer Control. 2013; 20:111-116.
7. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, RuschoffJ, Kang YK. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376:687-697.
8. Wei Q, Chen L, Sheng L, Nordgren H, Wester K, Carlsson J. EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases. Int J Oncol. 2007; 31:493-499.
9. Huang JX, Zhao K, Lin M, Wang Q, Xiao W, Lin MS, Yu H, Chen P, Qian RY. HER2 gene amplification in esophageal squamous cell carcinoma is less than in gastroesophageal junction and gastric adenocarcinoma. Oncol Lett. 2013; 6:13-18.
10. Kato H, Arao T, Matsumoto K, Fujita Y, Kimura H, Hayashi H, Nishiki K, Iwama M, Shiraishi O, Yasuda A, Shinkai M, Imano M, Imamoto H, Yasuda T, Okuno K, Shiozaki H, et al. Gene amplification of EGFR, HER2, FGFR2 and MET in esophageal squamous cell carcinoma. Int J Oncol. 2013; 42:1151-1158.
11. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R, 3rd, Le Beau MM, Earp HS, Liu ET. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol. 1991; 11:5016-5031.
12. Linger RMA, Keating AK, Earp HS, Graham DK. TAM receptor tyrosine kinases: Biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008; 100:35-83.
13. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res. 2002; 8:361-367.
14. Shieh YS, Lai CY, Kao YR, Shiah SG, Chu YW, Lee HS, Wu CW. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia. 2005; 7:1058-1064.
15. Tsou AP, Wu KM, Tsen TY, Chi CW, Chiu JH, Lui WY, Hu CP, Chang C, Chou CK, Tsai SF. Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics. 1998; 50:331-340.
16. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer. 1995; 60:791-797.
17. Nemoto T, Ohashi K, Akashi T, Johnson JD, Hirokawa K. Overexpression of protein tyrosine kinases in human esophageal cancer. Pathobiology. 1997; 65:195-203.
18. Gjerdrum C, Tiron C, Hoiby T, Stefansson I, Haugen H, Sandal T, Collett K, Li S, McCormack E, Gjertsen BT, Micklem DR, Akslen LA, Glackin C, Lorens JB. Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. P Natl Acad Sci USA. 2010; 107:1124-1129.
19. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia. 1999; 13:1352-1358.
20. Alvarez H, Montgomery EA, Karikari C, Canto M, Dunbar KB, Wang JS, Feldmann G, Hong SM, Haffner MC, Meeker AK, Holland SJ, Yu JX, Heckrodt TJ, Zhang J, Ding PY, GoffD, et al. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma. Cancer Biology & Therapy. 2010; 10:1009-1018.
21. Hong J, Peng DF, El-Rifai W, Belkhiri A. Regulation of Death-Inducing Signaling Complex by Axl Mediates TRAIL Resistance in Esophageal Adenocarcinoma. Gastroenterology. 2013; 144:S144-S144.
22. Hong J, Belkhiri A. AXL Mediates TRAIL Resistance in Esophageal Adenocarcinoma. Neoplasia. 2013; 15:296-+.
23. Hong J, Peng DF, Chen Z, Sehdev V, Belkhiri A. ABL Regulation by AXL Promotes Cisplatin Resistance in Esophageal Cancer. Cancer Research. 2013; 73:331-340.
24. Paccez JD, Duncan K, Vava A, Correa RG, Libermann TA, Parker MI, Zerbini LF. Inactivation of GSK3beta and activation of NF-kappaB pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell. 2015; 26:821-831.
25. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, Benzaken AO, Rodon J, Morse N, Yan JJ, Liu M, Das R, Chen Y, Tam A, Wang H, Liang J, et al. AXL mediates resistance to PI3Kalpha inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell. 2015; 27:533-546.
26. Liu L, Greger J, Shi H, Liu Y, Greshock J, Annan R, Halsey W, Sathe GM, Martin AM, Gilmer TM. Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL. Cancer Res. 2009; 69:6871-6878.
27. Liu L, Shi H, Liu Y, Anderson A, Peterson J, Greger J, Martin AM, Gilmer TM. Synergistic effects of foretinib with HER-targeted agents in MET and HER1-or HER2-coactivated tumor cells. Mol Cancer Ther. 2011; 10:518-530.
28. Torka R, Penzes K, Gusenbauer S, Baumann C, Szabadkai I, OrfiL, Keri G, Ullrich A. Activation of HER3 interferes with antitumor effects of Axl receptor tyrosine kinase inhibitors: suggestion of combination therapy. Neoplasia. 2014; 16:301-318.
29. Qian F, Engst S, Yamaguchi K, Yu P, Won KA, Mock L, Lou T, Tan J, Li C, Tam D, Lougheed J, Yakes FM, Bentzien F, Xu W, Zaks T, Wooster R, et al. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. Cancer Res. 2009; 69:8009-8016.
30. Hsu FM, Lee YC, Lee JM, Hsu CH, Lin CC, Tsai YC, Wu JK, Cheng JC. Association of clinical and dosimetric factors with postoperative pulmonary complications in esophageal cancer patients receiving intensity-modulated radiation therapy and concurrent chemotherapy followed by thoracic esophagectomy. Ann Surg Oncol. 2009; 16:1669-1677.
31. Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, Lee YC, Chia-Hsien Cheng J. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011; 81:e593-599.
32. Korst RJ, Kansler AL, Port JL, Lee PC, Kerem Y, Altorki NK. Downstaging of T or N predicts long-term survival after preoperative chemotherapy and radical resection for esophageal carcinoma. Ann Thorac Surg. 2006; 82:480-484; discussion 484-485.
33. Hu CP, Hsieh HG, Chien KY, Wang PY, Wang CI, Chen CY, Lo SJ, Wuu KD, Chang CM. Biologic properties of three newly established human esophageal carcinoma cell lines. J Natl Cancer Inst. 1984; 72:577-583.
34. Wuu KD, Cheng MY, Wang-Wuu S, Hu CP, Chang CM. Chromosome analysis on a cell line (CE48T/VGH) derived from a human esophageal carcinoma. Cancer Genet Cytogenet. 1986; 20:279-285.
35. Stoner GD, Kaighn ME, Reddel RR, Resau JH, Bowman D, Naito Z, Matsukura N, You M, Galati AJ, Harris CC. Establishment and characterization of SV40 T-antigen immortalized human esophageal epithelial cells. Cancer Res. 1991; 51:365-371.
36. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, Martin AM, Degenhardt Y, Rudolph SK, Haws TF, Jr., Hudson-Curtis BL, Gilmer TM. Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif. 2007; 40:580-594.
37. Zillhardt M, Park SM, Romero IL, Sawada K, Montag A, Krausz T, Yamada SD, Peter ME, Lengyel E. Foretinib (GSK1363089), an Orally Available Multikinase Inhibitor of c-Met and VEGFR-2, Blocks Proliferation, Induces Anoikis, and Impairs Ovarian Cancer Metastasis. Clin Cancer Res. 2011; 17:4042-4051.
38. Suzawa K, Toyooka S, Sakaguchi M, Morita M, Yamamoto H, Tomida S, Ohtsuka T, Watanabe M, Hashida S, Maki Y, Soh J, Asano H, Tsukuda K, Miyoshi S. Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations. Cancer Sci. 2016; 107:45-52.
39. Wong TW, Lee FY, Yu C, Luo FR, Oppenheimer S, Zhang HJ, Smykla RA, Mastalerz H, Fink BE, Hunt JT, Gavai AV, Vite GD. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling. Clin Cancer Res. 2006; 12:6186-6193.
40. Yang PW, Hung MC, Hsieh CY, Tung EC, Wang YH, Tsai JC, Lee JM. The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells. Lasers Med Sci. 2013; 28:605-614.
41. Yang PW, Chiang TH, Hsieh CY, Huang YC, Wong LF, Hung MC, Tsai JC, Lee JM. The effect of ephrin-A1 on resistance to Photofrin-mediated photodynamic therapy in esophageal squamous cell carcinoma cells. Lasers Med Sci. 2015; 30:2353-2361.
42. Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D. A Phase 2 Trial of Erlotinib in Patients With Previously Treated Squamous Cell and Adenocarcinoma of the Esophagus. Cancer. 2011; 117:1409-1414.
43. Dutton SJ, Ferry DR, Blazeby JM, Abbas H, Dahle-Smith A, Mansoor W, Thompson J, Harrison M, Chatterjee A, Falk S, Garcia-Alonso A, Fyfe DW, Hubner RA, Gamble T, Peachey L, Davoudianfar M, et al. Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial. Lancet Oncol. 2014; 15:894-904.
44. Janmaat ML, Gallegos-Ruiz MI, Rodriguez JA, Meijer GA, Vervenne WL, Richel DJ, Van Groeningen C, Giaccone G. Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients. Journal of Clinical Oncology. 2006; 24:1612-1619.
45. Rodriguez CP, Adelstein DJ, Rice TW, Rybicki LA, Videtic GMM, Saxton JP, Murthy SC, Mason DP, Ives DI. A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer. Journal of Thoracic Oncology. 2010; 5:229-235.
46. Digklia A, Voutsadakis IA. Targeted treatments for metastatic esophageal squamous cell cancer. World J Gastrointest Oncol. 2013; 5:88-96.
47. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett. 2008; 268:314-324.
48. Vuoriluoto K, Haugen H, Kiviluoto S, Mpindi JP, Nevo J, Gjerdrum C, Tiron C, Lorens JB, Ivaska J. Vimentin regulates EMT induction by Slug and oncogenic H-Ras and migration by governing Axl expression in breast cancer. Oncogene. 2011; 30:1436-1448.
49. Paccez JD, Duncan K, Vava A, Correa RG, Libermann TA, Parker MI, Zerbini LF. Inactivation of GSK3 beta and activation of NF-kappa B pathway via Axl represents an important mediator of tumorigenesis in esophageal squamous cell carcinoma. Mol Biol Cell. 2015; 26:821-831.
50. Bauer T, Zagorska A, Jurkin J, Yasmin N, Koffel R, Richter S, Gesslbauer B, Lemke G, Strobl H. Identification of Axl as a downstream effector of TGF-beta 1 during Langerhans cell differentiation and epidermal homeostasis. J Exp Med. 2012; 209:2033-2047.
51. Reichl P, Dengler M, van Zijl F, Huber H, Fuhrlinger G, Reichel C, Sieghart W, Peck-Radosavljevic M, Grubinger M, Mikulits W. Axl activates autocrine transforming growth factor-beta signaling in hepatocellular carcinoma. Hepatology. 2015; 61:930-941.
52. Lamouille S, Derynck R. Cell size and invasion in TGFbeta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway. J Cell Biol. 2007; 178:437-451.
53. Mak JCW, Chan-Yeung MMW, Ho SP, Chan KS, Choo K, Yee KS, Chau CH, Cheung AHK, Ip MSM, Study HKTSC. Elevated plasma TGF-beta(1) levels in patients with chronic obstructive pulmonary disease. Resp Med. 2009; 103:1083-1089.
54. Ciuclan L, Ehnert S, Ilkavets I, Weng HL, Gaitantzi H, Tsukamoto H, Ueberham E, Meindl-Beinker NM, Singer MV, Breitkopf K, Dooley S. TGF-beta enhances alcohol dependent hepatocyte damage via down-regulation of alcohol dehydrogenase I. J Hepatol. 2010; 52:407-416.
55. Pant I, Kumar N, Khan I, Rao SG, Kondaiah P. Role of Areca Nut Induced TGF-beta and Epithelial-Mesenchymal Interaction in the Pathogenesis of Oral Submucous Fibrosis. Plos One. 2015; 10.
56. Khan I, Kumar N, Pant I, Narra S, Kondaiah P. Activation of TGF-beta Pathway by Areca Nut Constituents: A Possible Cause of Oral Submucous Fibrosis. Plos One. 2012; 7.
57. Choueiri TK, Vaishampayan U, Rosenberg JE, Logan TF, Harzstark AL, Bukowski RM, Rini BI, Srinivas S, Stein MN, Adams LM, Ottesen LH, Laubscher KH, Sherman L, McDermott DF, Haas NB, Flaherty KT, et al. Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. J Clin Oncol. 2013; 31:181-186.
58. Ozawa Y, Nakamura Y, Fujishima F, Felizola SJ, Takeda K, Okamoto H, Ito K, Ishida H, Konno T, Kamei T, Miyata G, Ohuchi N, Sasano H. c-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic target. BMC Cancer. 2015; 15:451.